{"name":"Windtree Therapeutics","slug":"windtree","ticker":"WINT","exchange":"NASDAQ","domain":"windtreetx.com","description":"Windtree Therapeutics, Inc. is an American company which was set up in 1992 and now is based in Warrington, Pennsylvania, developing drug products for patients with respiratory disease. The company joined an alliance with Laboratorios del Dr. Esteve, S.A. In 2016, Discovery Laboratories changed name to Windtree Therapeutics, Inc.","hq":"Warrington, PA","founded":0,"employees":"","ceo":"Craig E. Fraser","sector":"Cardiovascular","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$40M","metrics":{"revenue":198000,"revenueGrowth":25.3,"grossMargin":0,"rdSpend":16276000,"netIncome":-1787000,"cash":27875000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Aerolize patent cliff ($10.0M at risk)","drug":"Aerolize","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Windtree Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Windtree Therapeutics reported its fourth quarter and full year 2023 financial results, with revenue of $1.2 million and a net loss of $14.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Windtree Therapeutics Announces Collaboration with Leading Research Institution","summary":"Windtree Therapeutics announced a collaboration with a leading research institution to develop new treatments for cardiovascular diseases.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-01-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNaFo5b2xUMDhLdTNoRkp3NzItVFZkZnIyaVNHTnV6WDE0T3prNzlyUzRoY181M2FQYmVHb0dqeTZmNkVYWGVoVnhTLXI3VE0yLUtLNVl0TW9xX2xVMjI0WmdWU0RjQ3VXc21OVmNjVk03WS1SUF9VM29UcjFMcXZnT3l6STAwV3NRSzVQVUtSWHBuYVZ5UVM1VWxsM3J6U1NfZG02TF8yOXpXaTFyM1E0TmZySUhmbE5Y?oc=5","date":"2025-12-23","type":"pipeline","source":"Stock Titan","summary":"Heart failure drug lineup sold, but seller keeps a slice of future sales - Stock Titan","headline":"Heart failure drug lineup sold, but seller keeps a slice of future sales","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxQVXhCMV9MSXN2NVdQVUo1M1VDVnJqWHI4YzNBSzhjN3hlOXZla1M5V1FVd1I5V0lXWExMNzgzdy0xNW5uUXNrVHdLRVlWMk9wOFFnSkpuZ1lnU1NNa212cFl5SVNtaHNheDBaWmZxWnZVOVN5TUNmRXNmQzZkd0ZqbVV0dUtHcExFYXB1QnJzaTNrZ0R1OHZ2TklHX1NqN3lSVTE1T2pxdEppTmdxZW5yNFVPWndYS0JpRk9SX202SG5DNFcwbVJZTEN3ajJsZlV2TFJXbEU1anhURE1TZEQ1TmVpQjdXdDRpT29CVG91RUxKSUxsanNWeEg4NA?oc=5","date":"2025-12-23","type":"pipeline","source":"GlobeNewswire","summary":"Windtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug Candidates - GlobeNewswire","headline":"Windtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug Candidates","sentiment":"neutral"},{"date":"2025-12-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-11-19","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-10-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-10-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-09-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-09-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE5PM2NGa29yTFFKVnNQVjYtZHNOSlhjeFZwYVNydW1FNVNQMUhjQXZMMERpWTVROEpxLW9aU1JwV0FMVWVnWFVnV3AyOG9vbDdhbDNKUGZhUGlDVTZMNnBzNTJ2VnpWMUFPQUVTcjJTX0s2bHJ5Y0RSMFJn?oc=5","date":"2025-08-28","type":"pipeline","source":"BUCKSCO.Today","summary":"Warrington’s Windtree Therapeutics Faces Uncertain Future After NASDAQ Delisting - BUCKSCO.Today","headline":"Warrington’s Windtree Therapeutics Faces Uncertain Future After NASDAQ Delisting","sentiment":"neutral"},{"date":"2025-08-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-08-19","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-08-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-08-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOSnpkdmhjaUdLSUx0SkRrc2xIMU5FZ3d1RXRoMVFjb1AyUkF5SnNyb0hFdF83bjV4ZE1nR2tpakVhMU1MSnNzTTl0TUxwa0RJRlhheWp3YlJLU19YenpPcjQyanh0a3pMUjZCOXpDMGhuM0txTXFfeEJKR09USTk3V3UtTVdHc0VjU2JWa3BHWFlEczQwc3YwU2ZCVk1XQk1yLS1vdC1CdVBxcldq?oc=5","date":"2025-08-04","type":"pipeline","source":"CoinDesk","summary":"BNB Tops $760 Amid Corporate Adoption and New Binance Features - CoinDesk","headline":"BNB Tops $760 Amid Corporate Adoption and New Binance Features","sentiment":"neutral"}],"patents":[{"drugName":"Aerolize","drugSlug":"bronchodilator","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":10000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Cardiovascular Systems","Boston Scientific","Abbott Laboratories"],"therapeuticFocus":["Cardiovascular Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":198000,"revenuePeriod":"2019-12-31","revenueHistory":[{"value":198000,"period":"2019-12-31"},{"value":158000,"period":"2019-06-30"},{"value":40000,"period":"2019-03-31"},{"value":1788000,"period":"2018-12-31"},{"value":304000,"period":"2018-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":16276000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-1787000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":27875000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}